In fight for GSK's Advair, generic firms step carefully on price

LONDON, June 3 (Reuters) - Generic drugmakers, hoping for

rich pickings from the launch of copies of GlaxoSmithKline's

best-selling Advair inhaler in the United States next

year, say they can win...

Read more